Know Cancer

or
forgot password

A Phase II Study Designed to Evaluate the Value of Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Head and Neck Cancer, Breast Cancer

Thank you

Trial Information

A Phase II Study Designed to Evaluate the Value of Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy

Inclusion Criteria


Inclusion criteria: For patients receiving radiation to the breast

1. Patients receiving a dose of at least 50 Gy in 25 fractions with concomitant
chemotherapy or treated with the McGill technique.

2. Patients able to understand and sign an informed consent form.

3. Patients that do not have active connective tissue disorders.

4. Patients 18 years or older.

5. Patients that did not receive any previous radiation.

6. Patients that do not have any known allergy to any ingredients of the NeoVIDERM cream

7. Patients need to be able to apply the creams themselves or have help with applying
the creams.

Inclusion criteria: For patients receiving radiation to the head and neck

1. Patients receiving radiotherapy on fields that include both sides of the neck

2. Patients able to understand and sign an informed consent form.

3. Patients that do not have active connective tissue disorders.

4. Patients 18 years or older.

5. Patients that did not receive any previous radiation.

6. Patients that do not have any known allergy to any ingredients of the NeoVIDERM cream

7. Patients need to be able to apply the creams themselves or have help with applying
the creams.

Exclusion criteria: For patients receiving radiation to the breast or the head and neck

1. Patients that have a type V or type VI skin type according to the Fitzpatrick scale
(because these patients will likely have less radiodermatitis and if they do, it will
be harder to evaluate it).

The Fitzpatrick Scale:

- Type I (scores 0-7) White; very fair; freckles. Always burns, never tans

- Type II (scores 8-16) White; fair. Usually burns, tans with difficulty

- Type III (scores 17-25) Beige; very common. Sometimes mild burn, gradually tans

- Type IV (scores 25-30) Beige with a brown tint; typical Mediterranean Caucasian
skin.

Rarely burns, tans with ease

- Type V (scores over 30) Dark brown. Very rarely burns, tans very easily

- Type VI Black. Never burns, tans very easily

2. Allergic to any ingredient in Neoviderm cream

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Maximum skin toxicity

Outcome Description:

The objective of this study is to determine the occurrence and degree of acute skin toxicity in patients receiving radical radiation therapy with preventive application of neoVIDERM compared to patients treated with institutional standard skin care.

Outcome Time Frame:

7 weeks post beginning of radiation treatments

Safety Issue:

Yes

Principal Investigator

Te Vuong, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Jewish General Hospital

Authority:

Canada: Research Ethics Office

Study ID:

11-053

NCT ID:

NCT01701466

Start Date:

December 2011

Completion Date:

December 2014

Related Keywords:

  • Head and Neck Cancer
  • Breast Cancer
  • Patients
  • with
  • Breast Neoplasms
  • Dermatitis
  • Head and Neck Neoplasms
  • Radiodermatitis

Name

Location